- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02053493
Nitrate's Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction (NEAT-HFpeF)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Delaware
-
Newark, Delaware, United States, 19718
- Christiana Care Health Services
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University School Of Medicine
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins Hospital
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hospital
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, United States, 02111
- Tufts Medical Center
-
West Roxbury, Massachusetts, United States, 02132
- Boston V.A. Healthcare System
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Missouri
-
St Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Duke University Medical Center
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, United States, 44106
- University Hospitals Case Medical Center
-
Cleveland, Ohio, United States, 44109
- Metro Health System
-
-
Pennsylvania
-
Lancaster, Pennsylvania, United States, 17604
- Lancaster General Hospital
-
Philadelphia, Pennsylvania, United States, 19107
- Jefferson Medical College
-
Philadelphia, Pennsylvania, United States, 19140
- Temple University Hospital
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania Health System
-
-
Texas
-
Houston, Texas, United States, 77030
- Michael E DeBakey VA Medical Center
-
-
Utah
-
Salt Lake CIty, Utah, United States, 84148
- V.A. Medical Center
-
Salt Lake City, Utah, United States, 84132
- University of Utah Hospitals and Clinics
-
-
Vermont
-
Burlington, Vermont, United States, 05401
- The University of Vermont - Fletcher Allen Health Care
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 50 years
- Symptoms of dyspnea (NYHA class II-IV) without evidence of a non-cardiac or ischemic explanation for dyspnea
- Ejection fraction (EF) ≥ 50% as determined on imaging study within 12 months of enrollment with no change in clinical status suggesting potential for deterioration in systolic function
Stable medical therapy for 30 days as defined by:
- No addition or removal of ACE, Angiotensin receptor blockers (ARBs), beta-blockers, calcium channel blockers (CCBs) or aldosterone antagonists
- No change in dosage of ACE, ARBs, beta-blockers,CCBs or aldosterone antagonists of more than 100%
One of the following within the last 12 months
- Previous hospitalization for heart failure (HF) with radiographic evidence of pulmonary congestion (pulmonary venous hypertension, vascular congestion, interstitial edema, pleural effusion) or
- Catheterization documented elevated filling pressures at rest (LVEDP≥15 or PCWP≥20) or with exercise (PCWP≥25) or
- Elevated NT-proBNP (> 400 pg/ml) or BNP (> 200 pg/ml) or
- Echo evidence of diastolic dysfunction / elevated filling pressures (at least two) E/A > 1.5 + decrease in E/A of > 0.5 with valsalva Deceleration time ≤ 140 ms Pulmonary vein velocity in systole < diastole (PVs<PVd)sinus rhythm) E/e'≥15 Left atrial enlargement (≥ moderate) Pulmonary artery systolic pressure > 40 mmHg Evidence of left ventricular hypertrophy
- LV mass/BSA ≥ 96 (♀) or ≥ 116 (♂) g/m2
- Relative wall thickness ≥ 0.43 (♂ or ♀) [(IVS+PW)/LVEDD]
- Posterior wall thickness ≥ 0.9 (♀) or 1.0 (♂) cm
- No chronic nitrate therapy or infrequent (≤ 1x week) use of intermittent sublingual nitroglycerin within last 3 months
- Ambulatory (not wheelchair / scooter / walker / cane dependent)
- HF is the primary factor limiting activity as indicated by answering # 2 to the following question:
My ability to be active is most limited by:
- Joint, foot, leg, hip or back pain
- Shortness of breath and/or fatigue and/or chest pain
- Unsteadiness or dizziness
- Lifestyle, weather, or I just don't like to be active
9. Body size allows wearing of the accelerometer belt as confirmed by ability to comfortably fasten the test belt provided for the screening process (belt designed to fit persons with BMI 20-40 Kg/m2 but belt may fit some persons outside this range)
10. Willingness to wear the accelerometer belt for the duration of the trial 11. Willingness to provide informed consent
Exclusion Criteria:
- Recent (< 3 months) hospitalization for HF
- Hemoglobin < 8.0 g/dl
- Glomerular filtration rate < 20 ml/min/1.73 m2 on most recent clinical laboratories
- SBP < 110 mmHg or > 180 mmHg at consent
- Diastolic blood pressure < 40 mmHg or > 100 mmHg at consent
- Resting HR > 110 bpm at consent
- Previous adverse reaction to nitrates necessitating withdrawal of therapy
- Chronic therapy with phosphodiesterase type-5 inhibitors (intermittent use of phosphodiesterase type-5 inhibitors for erectile dysfunction is allowable if the patient is willing to hold for the duration of the trial)
- Regularly (> 1x per week) swims or does water aerobics
- Significant COPD thought to contribute to dyspnea
- Ischemia thought to contribute to dyspnea
- Documentation of previous EF < 50%
- Acute coronary syndrome within 3 months defined by electrocardiographic changes and biomarkers of myocardial necrosis (e.g. troponin) in an appropriate clinical setting (chest discomfort or anginal equivalent)
- Percutaneous coronary intervention, coronary artery bypass grafting or new biventricular pacing within past 3 months
- Primary hypertrophic cardiomyopathy
- Infiltrative cardiomyopathy (amyloid)
- Constrictive pericarditis or tamponade
- Active myocarditis
- Complex congenital heart disease
- Active collagen vascular disease
- More than mild aortic or mitral stenosis
- Intrinsic (prolapse, rheumatic) valve disease with moderate to severe or severe mitral, tricuspid or aortic regurgitation
- Acute or chronic severe liver disease as evidenced by any of the following: encephalopathy, variceal bleeding, INR > 1.7 in the absence of anticoagulation treatment
- Terminal illness (other than HF) with expected survival of less than 1 year
- Enrollment or planned enrollment in another therapeutic clinical trial in the next 3 months
- Inability to comply with planned study procedures
- Pregnant women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Isosorbide Mononitrate
Isosorbide Mononitrate with dose up-titration (30 to 120 mg/day over 4 weeks)
|
Dispense phase 1 study drug: Weeks 1 and 2: No study drug (baseline) Week 3: 30 mg ISMN Week 4: 60 mg ISMN Weeks 5 and 6: 120 mg ISMN Dispense phase-2 study drug: Weeks 7 and 8: No study drug (washout) Week 9: 30 mg ISMN Week 10: 60 mg ISMN Weeks 11 and 12: 120 mg ISMN
Other Names:
|
Placebo Comparator: Isosorbide Mononitate Placebo
Isosorbide Mononitrate placebo with dose up-titration (30 to 120 mg/day over 4 weeks)
|
Dispense phase 1 study drug: Weeks 1 and 2: No study drug (baseline) Week 3: 30 mg Placebo Week 4: 60 mg Placebo Weeks 5 and 6: 120 mg Placebo Dispense phase-2 study drug: Weeks 7 and 8: No study drug (washout) Week 9: 30 mg Placebo Week 10: 60 mg Placebo Weeks 11 and 12: 120 mg Placebo |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Arbitrary Accelerometry Units (AAU) (Phase I)
Time Frame: 5-6 weeks
|
To evaluate whether isosorbide mononitrate increases daily activity as assessed by 14-day averaged arbitrary accelerometry units in comparison to placebo.
An arbitrary accelerometer unit is calculated within the accelerometer device that is worn by the patient and represents level of activity based on patient movement.
Higher values indicate more movement.
0 indicates no movement.
|
5-6 weeks
|
Arbitrary Accelerometry Units (AAU) (Phase II)
Time Frame: 11-12 weeks
|
To evaluate whether isosorbide mononitrate increases daily activity as assessed by 14-day averaged arbitrary accelerometry units in comparison to placebo.
An arbitrary accelerometer unit is calculated within the accelerometer device that is worn by the patient and represents level of activity based on patient movement.
Higher values indicate more movement.
0 indicates no movement.
|
11-12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Six Minute Walk Distance (Phase I)
Time Frame: Week 7
|
To evaluate whether isosorbide mononitrate (ISMN) improves functional capacity by 6 minute walk distance in comparison to placebo.
|
Week 7
|
Six Minute Walk Distance (Phase II)
Time Frame: Week 13
|
To evaluate whether isosorbide mononitrate (ISMN) improves functional capacity by 6 minute walk distance in comparison to placebo.
|
Week 13
|
Patient Preference for Isosorbide Mononitrate Treatment at the End of Study.
Time Frame: Week 13
|
Self reported participant preference for study period 1 vs. study period 2.
|
Week 13
|
Borg Score During 6 Minute Walk Test (Phase I)
Time Frame: Week 7
|
To evaluate whether isosorbide mononitrate improves quality of life in comparison to placebo.
The Borg Scale consists of scale range of 0 to 10 (where 0 indicates no breathlessness at all and 10 indicates maximum breathlessness).
Lower values are considered to be better than higher values.
|
Week 7
|
Borg Score During 6 Minute Walk Test (Phase II)
Time Frame: Week 13
|
To evaluate whether isosorbide mononitrate improves quality of life in comparison to placebo.
The Borg Scale consists of scale range of 0 to 10 (where 0 indicates no breathlessness at all and 10 indicates maximum breathlessness).
Lower values are considered to be better than higher values.
|
Week 13
|
Kansas City Cardiomyopathy Questionnaire Overall Summary Score (Phase I)
Time Frame: Week 7
|
To evaluate whether isosorbide mononitrate improves quality of life in comparison to placebo.
The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a disease-specific patient-reported outcomes measure for patients with heart failure.
It consists of 23 items, is comprised of 7 clinically relevant scales (Symptom Frequency, Symptom Burden, Symptom Stability, Physical Limitation, Social Limitation, Quality of Life, and Self-Efficacy), and yields 3 summary scores (Clinical Summary, Total Symptom, and Overall Summary Scores).
Scale and summary scores range between 0 and 100, with higher scores indicating better health status (eg, better functioning, fewer symptoms, better quality of life).
|
Week 7
|
Kansas City Cardiomyopathy Questionnaire Overall Summary Score (Phase II)
Time Frame: Week 13
|
To evaluate whether isosorbide mononitrate improves quality of life in comparison to placebo.
• The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a disease-specific patient-reported outcomes measure for patients with heart failure.
It consists of 23 items, is comprised of 7 clinically relevant scales (Symptom Frequency, Symptom Burden, Symptom Stability, Physical Limitation, Social Limitation, Quality of Life, and Self-Efficacy), and yields 3 summary scores (Clinical Summary, Total Symptom, and Overall Summary Scores).
Scale and summary scores range between 0 and 100, with higher scores indicating better health status (eg, better functioning, fewer symptoms, better quality of life).Higher values of the overall KCCQ score are considered to be better than lower values.
|
Week 13
|
N-terminal Pro-B-type Natriuretic Peptide Level (Phase I)
Time Frame: Week 7
|
To evaluate whether isosorbide mononitrate improves natriuretic peptide levels in comparison to placebo
|
Week 7
|
N-terminal Pro-B-type Natriuretic Peptide Level (Phase II)
Time Frame: Week 13
|
To evaluate whether isosorbide mononitrate improves natriuretic peptide levels in comparison to placebo
|
Week 13
|
Improvement in Daily Activity - Hours Active Per Day (Phase I)
Time Frame: 5-6 weeks
|
To evaluate whether isosorbide mononitrate in comparison to placebo improves daily activity as measured by Hours active per day during maximal dose of study drug
|
5-6 weeks
|
Improvement in Daily Activity - Hours Active Per Day (Phase II)
Time Frame: 11-12 weeks
|
To evaluate whether isosorbide mononitrate in comparison to placebo improves daily activity as measured by Hours active per day during maximal dose of study drug
|
11-12 weeks
|
Improvement in Daily Activity - Slope of Daily Average (Phase I)
Time Frame: 3-6 weeks
|
To evaluate whether isosorbide mononitrate in comparison to placebo improves daily activity as measured by Slope of daily averaged arbitrary accelerometry units during study drug administration.
An arbitrary accelerometer unit is calculated within the accelerometer device that is worn by the patient and represents level of activity based on patient movement.
Higher values indicate more movement.
0 indicates no movement.
|
3-6 weeks
|
Improvement in Daily Activity - Slope of Daily Average (Phase II)
Time Frame: 9-12 weeks
|
To evaluate whether isosorbide mononitrate in comparison to placebo improves daily activity as measured by Slope of daily averaged arbitrary accelerometry units during study drug administration.
An arbitrary accelerometer unit is calculated within the accelerometer device that is worn by the patient and represents level of activity based on patient movement.
Higher values indicate more movement.
0 indicates no movement.
|
9-12 weeks
|
Improvement in Daily Activity - Area Under the Curve (Phase I)
Time Frame: 3-6 weeks
|
To evaluate whether isosorbide mononitrate in comparison to placebo improves daily activity as measured by Area under the curve (AUC) of arbitrary accelerometry units during study drug administration.
An arbitrary accelerometer unit is calculated within the accelerometer device that is worn by the patient and represents level of activity based on patient movement.
Higher values indicate more movement.
0 indicates no movement.
Area under the curve is defined as ((7*average acceleromtery units/day during 30 mg) + (7*average acceleromtery units/day during 60 mg) + (14*average acceleromtery units/day during 120 mg))/28
|
3-6 weeks
|
Improvement in Daily Activity - Area Under the Curve (Phase II)
Time Frame: 9-12 weeks
|
To evaluate whether isosorbide mononitrate in comparison to placebo improves daily activity as measured by Area under the curve (AUC) of arbitrary accelerometry units during study drug administration.
An arbitrary accelerometer unit is calculated within the accelerometer device that is worn by the patient and represents level of activity based on patient movement.
Higher values indicate more movement.
0 indicates no movement.
Area under the curve is defined as ((7*average acceleromtery units/day during 30 mg) + (7*average acceleromtery units/day during 60 mg) + (14*average acceleromtery units/day during 120 mg))/28
|
9-12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kevin Anstrom, PhD, Duke Clinical Research Institute
Publications and helpful links
General Publications
- Reddy YNV, Rikhi A, Obokata M, Shah SJ, Lewis GD, AbouEzzedine OF, Dunlay S, McNulty S, Chakraborty H, Stevenson LW, Redfield MM, Borlaug BA. Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity. Eur J Heart Fail. 2020 Jun;22(6):1009-1018. doi: 10.1002/ejhf.1788. Epub 2020 Mar 9.
- Snipelisky D, Kelly J, Levine JA, Koepp GA, Anstrom KJ, McNulty SE, Zakeri R, Felker GM, Hernandez AF, Braunwald E, Redfield MM. Accelerometer-Measured Daily Activity in Heart Failure With Preserved Ejection Fraction: Clinical Correlates and Association With Standard Heart Failure Severity Indices. Circ Heart Fail. 2017 Jun;10(6):e003878. doi: 10.1161/CIRCHEARTFAILURE.117.003878.
- Redfield MM, Anstrom KJ, Levine JA, Koepp GA, Borlaug BA, Chen HH, LeWinter MM, Joseph SM, Shah SJ, Semigran MJ, Felker GM, Cole RT, Reeves GR, Tedford RJ, Tang WH, McNulty SE, Velazquez EJ, Shah MR, Braunwald E; NHLBI Heart Failure Clinical Research Network. Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2015 Dec 10;373(24):2314-24. doi: 10.1056/NEJMoa1510774. Epub 2015 Nov 8.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00050042
- 4U10HL084904-10 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
US Department of Veterans AffairsCompleted
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
Clinical Trials on Isosorbide Mononitrate
-
Danish Headache CenterCompleted
-
Cairo UniversityCompletedIUD Insertion PainEgypt
-
BayerMerck Sharp & Dohme LLCCompletedCoronary Artery DiseaseGermany
-
Biolab Sanus FarmaceuticaWithdrawn
-
Biolab Sanus FarmaceuticaWithdrawnHealthy Subjects | Pharmacokinetics
-
Cairo UniversityUnknown
-
Aljazeera HospitalSuez Canal UniversityUnknown
-
The University of Texas Health Science Center,...National Kidney FoundationTerminatedHypertension | Proteinuria | Kidney InjuryUnited States
-
Al-Azhar UniversityNot yet recruiting
-
Torrent Pharmaceuticals LimitedCompleted